Safety and Immunological Response following homologous or heterologous booster COVID-19 vaccination (3rd dose study)
- Conditions
- healthy volunteershealthcare workers
- Registration Number
- TCTR20210719006
- Lead Sponsor
- Faculty of Medicine Siriraj Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 360
Males or females at least 18 years of age (inclusive)
- Have received 2nd dose of COVID-19 vaccine (CoronaVac or ChAdOx1) for 8-12 weeks earlier
- Can understand Thai language through speaking, reading and writing
- Able to communicate through electronic tools such as Google form or line
- Capable of attending all study visits according to the study schedule
- Capable of informed consent and provision of written informed consent before any study procedures
- Have history of severe drug or vaccine allergy (anaphylaxis)
- Have detected COVID-19 infection within the last 90 days
- Have received blood transfusion, plasma, blood product, blood components, immunoglobulins, antiviral or antibodies within the last 90 days
- Have history of cigarettes smoking, alcohol drinking and history of drug abuse
- Be pregnant
- Have unstable disease or could not control the symptom
- Have history of immunodeficiency or use immunosuppressant or steroid drugs
- Have any unusual symptoms or medical history that considered unable to participate in the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Adverse events within 7 days after booster vaccine Proportion of Adverse events
- Secondary Outcome Measures
Name Time Method Immunological response including antibody level and cell mediated immune response 2 weeks and 16-20 weeks after vaccine IgG level, NT test, IGRA test